Cargando…
Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/ https://www.ncbi.nlm.nih.gov/pubmed/28421338 http://dx.doi.org/10.1007/s00592-017-0994-x |
_version_ | 1783249221079531520 |
---|---|
author | Roberts, Carl A. Christiansen, Paul Halford, Jason C. G. |
author_facet | Roberts, Carl A. Christiansen, Paul Halford, Jason C. G. |
author_sort | Roberts, Carl A. |
collection | PubMed |
description | Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorcaserin and phentermine/topiramate, which have FDA approval only. Each of the six drugs, used singly or in combination, has distinct pharmacological, and presumably distinct behavioural, mechanisms of action, thus the potential to provide defined therapeutic options to personalise the management of obesity. Yet, with regard to pharmacotherapy for obesity, we are far from true personalised medicine. We review the limited mechanistic data with four mono and combination pharmacotherapies, to assess the potential for tailoring their use to target specific obesogenic behaviours. Potential treatment options are considered, but in the absence of adequate research in respect to effects of these drugs on eating behaviour, neural activity and psychological substrates that underlie poorly controlled eating, we are far from definitive therapeutic recommendations. Specific mechanistic studies and broader behavioural phenotyping, possibly in conjunction with pharmacogenetic research, are required to characterise responders for distinct pharmacotherapeutic options. |
format | Online Article Text |
id | pubmed-5504125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-55041252017-07-25 Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? Roberts, Carl A. Christiansen, Paul Halford, Jason C. G. Acta Diabetol Review Article Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorcaserin and phentermine/topiramate, which have FDA approval only. Each of the six drugs, used singly or in combination, has distinct pharmacological, and presumably distinct behavioural, mechanisms of action, thus the potential to provide defined therapeutic options to personalise the management of obesity. Yet, with regard to pharmacotherapy for obesity, we are far from true personalised medicine. We review the limited mechanistic data with four mono and combination pharmacotherapies, to assess the potential for tailoring their use to target specific obesogenic behaviours. Potential treatment options are considered, but in the absence of adequate research in respect to effects of these drugs on eating behaviour, neural activity and psychological substrates that underlie poorly controlled eating, we are far from definitive therapeutic recommendations. Specific mechanistic studies and broader behavioural phenotyping, possibly in conjunction with pharmacogenetic research, are required to characterise responders for distinct pharmacotherapeutic options. Springer Milan 2017-04-19 2017 /pmc/articles/PMC5504125/ /pubmed/28421338 http://dx.doi.org/10.1007/s00592-017-0994-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Roberts, Carl A. Christiansen, Paul Halford, Jason C. G. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title | Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title_full | Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title_fullStr | Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title_full_unstemmed | Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title_short | Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? |
title_sort | tailoring pharmacotherapy to specific eating behaviours in obesity: can recommendations for personalised therapy be made from the current data? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/ https://www.ncbi.nlm.nih.gov/pubmed/28421338 http://dx.doi.org/10.1007/s00592-017-0994-x |
work_keys_str_mv | AT robertscarla tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata AT christiansenpaul tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata AT halfordjasoncg tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata |